HC Wainwright Expects Lower Earnings for Abeona Therapeutics

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Analysts at HC Wainwright cut their Q1 2026 EPS estimates for shares of Abeona Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($0.32) for the quarter, down from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at $0.01 EPS and FY2027 earnings at ($0.47) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.65 million.

Several other research analysts have also recently issued reports on ABEO. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a report on Tuesday, March 17th. Finally, Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $4.42 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.74 and a current ratio of 6.93. The company has a market capitalization of $252.16 million, a PE ratio of 4.29 and a beta of 1.13. The company has a 50 day moving average price of $5.06 and a 200-day moving average price of $5.16. Abeona Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $7.54.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Goldman Sachs Group Inc. raised its holdings in Abeona Therapeutics by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock worth $954,000 after purchasing an additional 66,422 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Abeona Therapeutics by 129.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Abeona Therapeutics in the 2nd quarter worth approximately $63,000. Creative Planning raised its stake in shares of Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 4,305 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Abeona Therapeutics during the second quarter valued at approximately $120,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Insider Buying and Selling

In other Abeona Therapeutics news, Director Eric Crombez sold 16,284 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $82,885.56. Following the completion of the sale, the director owned 63,456 shares in the company, valued at $322,991.04. This represents a 20.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vishwas Seshadri sold 69,832 shares of Abeona Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total value of $372,204.56. Following the completion of the transaction, the chief executive officer owned 1,460,408 shares in the company, valued at $7,783,974.64. This represents a 4.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 209,605 shares of company stock valued at $1,101,300 over the last ninety days. Company insiders own 5.40% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.